Search

Secondary causes of diabetes are uncommon but early recognition is important so that patients receive appropriate diagnosis and treatment. Cushing's syndrome is a rare disorder which is associated with weight gain, diabetes and hypertension. Since obesity is common in type 2 diabetes, a diagnosis of Cushing's syndrome may be easily overlooked. Herein we describe resistant/refractory hypertension as a clinical clue to suspect Cushing's syndrome in patients with diabetes. [ABSTRACT FROM AUTHOR]

While advancements in the treatment of diabetes continue to rapidly evolve, many of the newer technologies have financial barriers to care, opposing the egalitarian ethos of Banting who sold his patent on insulin for a nominal cost to allow it to be made widely available. Inequity in access to new therapies drives disparity in diabetes burden with potential for these gaps to widen in the future. The 2023 International Conference on Advanced Technologies and Treatments of Diabetes (ATTD) presented ground-breaking and current research in diabetes technology. Oral presentations of the ATTD conference 2023 were analyzed to describe what percentage of speakers discussed equity in their talks. Overall, less than a quarter of presenters discussed equity, though there was regional variation. To ensure that diabetes technologies reduce disparity and improve outcomes, we encourage future speakers at diabetes (technology) conferences to consider equity of diabetes care and incorporate this into their presentations., Competing Interests: MD declares receiving speaker fees from Medtronic, Dexcom, Boerhinger Ingelheim, research support from Dexcom, Medtronic, Novonordisk, Pfizer, SOOIL, and has served as advisory board membership for Dexcom. RL receives consulting fees from Abbott DIabetes Care, Gluroo, PhysioLogic Devices, Provention Bio and is chief medical advisor for Tidepool. He receives research support from NIDDK 1K23DK122017 and P30 DK116074, JDRF, Abbott, Insulet, Medtronic and Tandem. ED declares receiving speaker fees from Lilly, and being part of speaker’s bureau for Dexcom. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Leadley, Addala, Berkeley, Crocket, Davis, Hewapathirana, Hussain, Lal, Lomax, Wilkinson, de Bock and Burckhardt.)